Matching “Wanted Posters” With Immune Hunters in Tumor Sections: Slide-GoTags Maps the Neoantigen–Immune Battle

A core challenge in cancer immunotherapy is that even when a tumor is packed with immune cells, this does not mean they actually recognize the cancer cells beside them. In a study published in *Nature Biotechnology*, a research team introduced the Slide-GoTags platform, which places the neoantigens carried by cancer cells, the T cells infiltrating the tumor, and their receptor sequences onto the same spatial map, allowing researchers to see which immune cells may be recognizing which cancer cells.

Neoantigens are protein fragments generated by tumor mutations that are usually absent from normal cells. They are also important targets for personalized cancer vaccines and some cell therapies. Previously, researchers could separately identify tumor mutations, analyze gene expression, or sequence T-cell receptors, but breaking down the tissue often erased the cells’ original locations, making it difficult to determine whether specific T cells were actually near cancer cells carrying the corresponding antigens.

Slide-GoTags integrates targeted tumor genotyping, T-cell receptor sequencing, and single-nucleus RNA sequencing within the same tissue section. It not only marks which cancer cells express candidate neoantigens but also identifies the transcriptional states and receptor sequences of nearby T cells, enabling antigens and potentially matching immune receptors to be tracked at single-cell resolution.

The researchers identified clonally expanded, neoantigen-specific T cells in mouse and human tumors; these cells were located near cancer cells expressing the corresponding antigens. An accompanying research briefing noted that the analysis also identified distinct immune microenvironments associated with tumor-specific responses, indicating that effective recognition is not uniformly distributed but may be concentrated in specific “immune niches.”

Publicly available data also allow some of the results to be examined further. The Broad Institute’s Single Cell Portal hosts data used for some of the human tumor figures in the paper, covering a total of 78,651 cells and 30,489 genes, and provides interactive exploration and downloads. This can help other researchers examine the spatial colocalization of neoantigen-positive cancer cells and corresponding T cells or retest the conclusions using different analytical methods.

The near-term value of this method is more likely to lie in helping researchers select neoantigens that can genuinely trigger T-cell responses within tumors and in clarifying why some immune responses are effective while others are suppressed by the microenvironment. Before it can be used further in the design of personalized vaccines or cell therapies, it still needs to be validated across more cancer types and larger patient cohorts. Researchers must also confirm whether spatial proximity represents actual and sustained antitumor activity; the current study cannot yet demonstrate that selecting targets on this basis improves clinical efficacy.